Demographics, anthropometrics and cardiovascular risk factors in adults with latent autoimmune diabetes (LADA), type 1 diabetes (T1D) and type 2 diabetes (T2D): Findings from the DPV registry in Germany and Austria
Diabetologie und Stoffwechsel, vol. 19, pp. S36–S37
Abstract
Introduction : Our aim was to characterize and compare people diagnosed with T1D, T2D, or LADA in a real world setting to better understand the clinical impact of the diagnosis LADA. Methods : We analyzed data from 36,959 adults with type 1, type 2 diabetes or LADA between 30 and 70 years of age with data available at diabetes diagnosis and follow-up. People were enrolled in the prospective Diabetes Patients Follow-Up (DPV) registry from 1995 to 2022. LADA was defined as clinical diagnosis of type 2 diabetes and positivity of ≥ 1 islet autoantibody and an insulin-free interval of ≥ 6 months upon diabetes diagnosis. Anthropometric and clinical data were compared between LADA, T1D and T2D in a cross-sectional setting at diagnosis and follow-up ( ≥ 6 months after diagnosis). Results : At diagnosis, demographic and anthropometric measurements (age at diagnosis, BMI, waist circumference), C-peptide level and HbA1c in people with LADA (n=747) fell in between T1D (n=940) and T2D (n=35,272) (all p-values<0.01). Median duration of diabetes at follow-up was 3.47 years for those with T2D, 3.77 years for those with LADA and 3.9 years for those with T1D. At follow-up, people with LADA exhibited a higher prevalence of dyslipidemia, arterial hypertension and nephropathy than those with T2D and T1D (all p<0.01). This remained statistically significant after adjusting for age, sex and diabetes duration. Dyslipidemia was reported in 90.6% of people with LADA, in 81.8% with T2D, and in 75.7% with T1D. Interestingly, only 36.6%, 18.2% and 15% received lipid-lowering treatment, respectively. Hypertension was reported in 77.7% of those with LADA, 60.4% of those with T2D, and 39.7% of those with T1D, but only 63%, 29.4% and 22.4% received antihypertensive treatment, respectively. Nephropathy was reported in 44.2% of people with LADA at follow-up, followed by those with T2D (38.5%) and then T1D (19.9%). Peripheral neuropathy was reported in 55.1% of people with LADA, in 43.9% of people with T2D and 42.1% of those with T2D (LADA vs T2D p<0.01, LADA vs T1D n.s.). Conclusion : People with LADA fell in between T1D and T2D with regard to age at diagnosis, BMI and waist circumference, as expected. However, people with LADA had a higher prevalence of cardiovascular risk factors such as dyslipidemia, hypertension, nephropathy and peripheral neuropathy, which suggests that people with LADA are at increased cardiovascular risk. Publication History Article published online: 18 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Authors 9
-
Düsseldorf University Hospital · Heinrich Heine University Düsseldorf
Affiliation as printed
Heinrich Heine University Düsseldorf, Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany
-
Affiliation as printed
Ulm University, Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany
-
Düsseldorf University Hospital · Heinrich Heine University Düsseldorf
Affiliation as printed
University Children's Hospital Düsseldorf, Department of General Paediatrics, Neonatology and Paediatric Cardiology, Düsseldorf, Germany
-
Affiliation as printed
RWTH Aachen University, Division of Endocrinology and Diabetes, Aachen, Germany
-
Affiliation as printed
University Lübeck, Division of Endocrinology and Diabetes, Lübeck, Germany
-
Affiliation as printed
Helmholtz Center Munich, Research Group Diabetes e.V, Munich, Germany
-
Affiliation as printed
Medical University of Graz, Division of Endocrinology and Diabetology, Graz, Austria
-
Affiliation as printed
Vivantes Clinic Kaulsdorf, Department of Gastroenterology, Diabetology and Geriatrics, Berlin, Germany
-
Affiliation as printed
Ulm University, Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany
Cited by 0 stored of 0
No patents citing this paper on Lens.org (checked 2026-10-06).